OrganiGram (OGI) Q4 2024 earnings summary

Executive summary

• Fiscal 2024 featured four consecutive quarters of net revenue growth, rising adjusted gross margins, and a 55% increase in full-year adjusted EBITDA, with net revenue reaching $159.8 million, up 6% year-over-year.

• Achieved #1 Canadian market share post-Motif acquisition, with leading positions in vapes, pre-rolls, hash, concentrates, and milled flower.

• Strategic investments included a CAD 124.6 million ($124.6M) BAT investment, a $21M stake in Germany's Sanity Group, and the creation of the CAD 83 million Jupiter Fund for international expansion.

• Closed two tranches of the BAT investment and a $28.8 million equity offering, strengthening liquidity and supporting global growth.

• Net loss narrowed significantly to $45.4 million from $247.0 million in the prior year, reflecting improved margins and lower impairments.

Financial highlights

• Q4 net revenue grew 10% sequentially and 22% year-over-year to $44.7 million, with cost of sales down 10% to $30.9 million.

• Adjusted gross margin reached 37% in Q4, up from 20% in the prior year quarter; full-year adjusted gross margin was 34%, up from 25%.

• Q4 adjusted EBITDA was $5.9 million, up 69% sequentially and 10,003% year-over-year; full-year adjusted EBITDA rose 55% to $8.4 million.

• Q4 net loss improved to $5.4 million from $26.6 million; full-year net loss improved to $45.4 million from $247.0 million.

• Cash and short-term investments at year-end were $133.4 million, with a pro-forma cash position of ~$120 million post-Motif acquisition and BAT investment.

Outlook and guidance

• Fiscal 2025 is expected to deliver higher adjusted EBITDA and positive cash flow from operations, with gross margins anticipated to stabilize above 35% and continued cost synergies from the Motif acquisition.

• EU-GMP certification at the Moncton facility is expected in early 2025, enabling higher-margin international sales.

• Final $41.5 million BAT investment tranche is expected to close in February 2025, further enhancing liquidity.

• Targeting 20% of cannabis harvests from seeds in Fiscal 2025 to reduce cultivation costs, with monthly fluctuations between 15% and 30%.

• Canadian cannabis market projected to grow 4% in 2025, with opportunities to gain share as smaller players exit.